1. Product Overview
GSK484 hydrochloride (CAS: 1652591-81-5) is a potent, selective, and reversible benzimidazole-derived inhibitor of peptidylarginine deiminase 4 (PAD4, also known as PADI4). As a hydrochloride salt form optimized for research use, it targets the calcium-sensitive PAD4 enzyme responsible for citrullination — the post-translational conversion of arginine residues to citrulline on histone tails and other substrates. With an IC₅₀ of 50 nM in the absence of calcium and 250 nM in the presence of 2 mM calcium, GSK484 provides researchers with a precise pharmacological tool to dissect PAD4-mediated pathways in rheumatoid arthritis, lupus, cancer-associated inflammation, and neutrophil extracellular trap (NET) formation (NETosis). Unlike irreversible pan-PAD inhibitors, GSK484’s reversible binding kinetics and high isoform selectivity make it the gold-standard probe for mechanistic studies of protein citrullination.
2. Key Features and Advantages
• High Selectivity Profile: Exhibits >50-fold selectivity for PAD4 over other PAD isoforms (PAD1, PAD2, PAD3) at working concentrations, minimizing off-target citrullination effects in complex cellular systems.
• Reversible Inhibition Mechanism: Binds reversibly to the low-calcium conformation of PAD4, allowing temporal control of inhibition in washout experiments and dynamic pathway dissection.
• Calcium-Dependent Activity: Displays pronounced calcium sensitivity (IC₅₀ shifts from 50 nM at 0 mM Ca²⁺ to 250 nM at 2 mM Ca²⁺), faithfully mimicking physiological PAD4 regulation and enabling calcium-gated assay designs.
• Research-Grade Consistency: Supplied at ≥98% purity (HPLC), with full structural verification by ¹H NMR, LC-MS, and elemental analysis; batch-specific CoA provided for reproducibility across Western blot, ELISA, and in vivo studies.
• Proven In Vivo Efficacy: Documented to suppress NETosis and reduce proteinuria in MMTV-PyMT tumor-bearing mice at 4 mg/kg/day without detectable toxicity, supporting its use in preclinical rodent models.
• Optimized Salt Form: The hydrochloride salt enhances aqueous solubility (≈2 mg/mL in warmed water; 25 mg/mL in DMSO) and solid-state stability compared to the free base, simplifying both in vitro and in vivo formulation.
3. Main Applications
• Autoimmune Disease Research: Widely used in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) models to investigate how PAD4-driven citrullination of fibrinogen, vimentin, and histones generates anti-citrullinated peptide antibodies (ACPAs) and drives joint inflammation.
• NETosis & Innate Immunity Studies: Applied in primary human/mouse neutrophil assays (immunofluorescence, live-cell imaging, ELISA for MPO-DNA complexes) to quantify NET release and evaluate PAD4’s role in infection, sepsis, thrombosis, and COVID-19-associated immunothrombosis.
• Oncology & Tumor Microenvironment: Employed in cancer models (e.g., MMTV-PyMT breast cancer, colorectal carcinoma) to study PAD4-mediated neutrophil recruitment, metastatic niche formation, and tumor-promoted kidney injury via NET-dependent mechanisms.
• Epigenetics & Chromatin Biology: Used in histone citrullination tracking (citH3 Arg2/8/17 Western blots) to distinguish PAD4-dependent chromatin remodeling from other post-translational modifications during gene activation or cellular differentiation.
• High-Throughput Screening Counter-Screen: Serves as a selective reference inhibitor in PAD4-targeted drug discovery campaigns and orthogonal validation of novel irreversible or allosteric PAD4 probes.
• In Vivo Pharmacodynamics: Administered intraperitoneally or orally in mice (typical dose 4–10 mg/kg/day) to assess urinary protein reduction, circulating NET markers, and synovial citrullination in disease models.
4. Technical Specifications
5. Storage and Handling
• Powder Storage: Store the sealed original vial at 2–8°C in a refrigerator, protected from light and moisture with desiccant present. Under these conditions the powder remains stable for at least 24 months. For archival storage (>2 years), a -20°C freezer with inert atmosphere is recommended.
• Reconstitution: Allow the vial to equilibrate to room temperature before opening to prevent moisture condensation. Briefly centrifuge to collect material. For in vitro assays, dissolve in anhydrous DMSO to prepare a 10–25 mM stock solution (clear upon gentle vortexing/sonication). For in vivo studies, GSK484 can be dissolved in warm PBS (≈2 mg/mL) or formulated in 5% DMSO + 95% corn oil / saline with mild warming.
• Solution Storage: Aliquot DMSO stocks into single-use volumes (e.g., 10–50 µL) immediately after preparation. Store aliquots at -20°C (short-term, ≤6 months) or -80°C (long-term, up to 12 months). Strictly avoid repeated freeze-thaw cycles; thaw only the required aliquot on ice before use.
• Handling Precautions: Use in a well-ventilated area or fume hood. Wear nitrile gloves, safety goggles, and a lab coat. Minimize dust generation; do not inhale powder. Keep container tightly closed when not in use.
6. Safety Overview
GSK484 hydrochloride is intended strictly for Laboratory Research Use Only (LRUO). It is not for human or veterinary diagnostic, therapeutic, or consumable use. Classified under GHS07 with warning label: H302 (Harmful if swallowed), H315 (Causes skin irritation), H319 (Causes serious eye irritation), H335 (May cause respiratory irritation). In case of contact with skin, wash immediately with plenty of soap and water. In case of eye contact, rinse cautiously with flowing water for at least 15 minutes and seek medical advice. If inhaled, move to fresh air. Dispose of as hazardous organic chemical waste per local regulations (WGK 3, environmentally hazardous). Always consult the full Safety Data Sheet (SDS) prior to handling.